Connect with us


First expandable deep brain access port will help cancer surgeries 

Avatar photo



The world’s first expandable deep brain access port has been made available to neurosurgeons after successful human use in surgical treatment. 

The Cerevention MindsEye Expandable Port provides a new level of access and visualisation during surgical treatment of stroke, cancer, and other conditions – and has been brought to the market after proven, successful use.

The minimally invasive port, which will improve surgeons’ expandability, insertion and removal, and transparency, has been noted as “truly unique.”

Mizuho America has now secured an exclusive agreement to distribute the MindsEye expandable port to neurosurgeons in the US. 

William Delaney, vice president of sales said: “Mizuho’s mission is to deliver the best devices to neurosurgeons.

“The MindsEye expandable port is a device like no other. We look forward to bringing it to the market by leveraging the strength of our neuro-portfolio and distribution channel to make an immediate impact on the ease of procedures for surgeons and quality of life for patients.” 

Rigorous comparisons of options for minimally invasive neurosurgical procedures were carried out before choosing the MindsEye expandable port.

The device is being used in human treatments at Tulane University by Dr. Art Wang and Dr. Johnny Delashaw, who conducted the project. 

The “next generation” of deep brain access

Dr. Mario Zuccarello, professor of neurosurgery at University of Cincinnati Medical Center, said this step is the “next generation” of deep brain access technology. 

He added: Its distal flare design supports real-time changes in plans and instrumentation and eliminates the need to remove and up-size to larger ports, which can cause unnecessary damage. 

“Decreased tissue disruption throughout the procedure helps reduce procedural risk and can promote earlier intervention and accelerated healing.” 

Matt Adams, Cerevention general manager commented: “We are very excited to bring Cerevention’s innovation together with Mizuho’s strength in the neuro sales channel. This partnership will allow surgeons across the country to access this advanced technology.”

Continue Reading
1 Comment

1 Comment

  1. Pingback: AdvanCell closes A$18M Series B funding round | Health Tech World

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories